Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.
2020A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Mease, P.J.; Smolen, J.S.; Behrens, F.; Nash, P.; Liu Leage, S.; Li, L.; Tahir, H.; Gooderham, M.; Krishnan, E.; Liu-Seifert, H.; Emery, P.; Pillai, S.G.; Helliwell, P.S.
2020Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): A double-blind, parallel-group, randomised, active-controlled, phase 3b trial
McInnes, I.B.; Behrens, F.; Mease, P.J.; Kavanaugh, A.; Ritchlin, C.; Nash, P.; Masmitja, J.G.; Goupille, P.; Korotaeva, T.; Gottlieb, A.B.; Martin, R.; Ding, K.; Pellet, P.; Mpofu, S.; Pricop, L.
2019Achievement Of CDAPSA Low Disease Activity Or Remission Is Associated With Control Of Articular And Extra-Articular Manifestations Of Active Psoriatic Arthritis In Subjects Treated With Apremilast
Coates, L.C.; Mease, P.J.; Behrens, F.; Orbai, A.M.; Ogdie, A.; Brunori, M.; Teng, L.; Guerette, B.; Smolen, J.S.
2019Probability Of Achieving Low Disease Activity Or Remission In Subjects With Active Psoriatic Arthritis Treated With Apremilast
Mease, P.J.; Behrens, F.; Gladman, D.D.; Kavanaugh, A.; Brunori, M.; Teng, L.C.; Guerette, B.; Queiro, R.; Ogdie, A.